Current practice in military blood transfusion is to use specific IV bags and chemical preservatives to transfer blood from the donor to the injured recipient. Our goal is to study if this blood transfusion can occur using a basic syringe without any preservative. This will help military personnel in areas will limited resources to provide blood transfusions to injured soldiers and save lives. We will also be evaluating ultrasound techniques which determine if a patient needs fluid (either regular IV fluid or blood transfusion).
In this study, we want to interview women with pregnancy Medicaid in North Carolina. We would like to learn what would help more people go to the dentist and get dental care during this time. That way, we can make suggestions for policy changes to help more people get the care they need.
This study is assessing the effectiveness and safety of tiragolumab, an anti-TIGIT monoclonal antibody, when given with atezolizumab and bevacizumab as a first-line treatment for unresectable, locally advanced or metastatic patients with hepatocellular carcinoma (HCC). TIGIT is thought to play an important role in HCC's response to immunotherapy treatments such as atezolizumab. This study will assess whether the addition of tiragolumab to atezolizumab and bevacizumab will improve response and clinical outcomes.
Fuel for Thought: How do sugar and fat affect each other in the brain? Do you ever wonder what happens in your brain when you eat dessert? And why sugary and fatty foods are so appealing? If so, you may eligible to participate in a research study to understand the impact of sugar and fat on the brain!
Since Crisfield's founding on the Chesapeake Bay, the environment has been an important part of community life, economy and culture. In an effort to deal with current environmental challenges such as nuisance flooding, storms, and erosion, the U.S. Environmental Protection Agency is partnering with the City of Crisfield and Maryland Sea Grant to explore nature-based solutions to flooding such as green infrastructure and marsh restoration. Join a team of Crisfield area residents in the Crisfield Resilience Academy to work with scientists and co-develop community solutions to issues associated with local flooding. For additional information, please join the upcoming informational webinar or contact Jenna Hartley at hartley.jenna@epa.gov. Crisfield Resilience Academy participants will receive a stipend of up to $400/six months for participating.
If you have high risk prostate cancer, you may be able to participate in a research study to find out decreasing or increasing your radiation and hormonal therapy has an effect on your cancer.
In this study, we want to learn if a combination of two drugs (fianlimab and cemiplimab) is an effective treatment compared to a drug called pembrolizumab for people who have had melanoma removal surgery but are still at high risk for recurrence of the disease.
This is a Phase 1b/2, multicenter, open-label, basket study evaluating ACR-368, an adenosine triphosphate-competitive selective inhibitor of checkpoint kinase (CHK)1 and CHK2, as monotherapy and in combination with ultralow-dose gemcitabine (ULDG), in the treatment of subjects with histologically confirmed, locally advanced or metastatic, recurrent platinum-resistant high-grade ovarian or endometrial adenocarcinoma, or platinum-resistant urothelial carcinoma (hereafter referred to as ovarian, endometrial, and urothelial, respectively).
The purpose of this study is to investigate age effects on foot-ankle mechanical power interactions in walking and their underlying mechanisms to improve walking performance and economy in older adults.
Have you been diagnosed with a locally advanced or metastatic solid tumor cancer? Are there no available curative treatment options, or has your prior standard of care treatment failed? You may be able to take part in this gene therapy research study to learn more about using your own modified immune cells as a possible treatment.